Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Sultanik, Philippe; Mallet, Vincent; Lagaye, Sylvie; Casrouge, Armanda; Dorival, Céline; Barthe, Yoann; Fontaine, Hélène; Hézode, Christophe; Mottez, Estelle; Bronowicki, Jean-Pierre; Carrat, Fabrice; Theodorou, Ioannis; Abel, Laurent; Gayat, Etienne; Fontanet, Arnaud; Pol, Stanislas; Albert, Matthew L.
; 35(7): 1833-44, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25556540
Optimal treatment with boceprevir for chronic HCV infection.
Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.
Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.
Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.